SCHEMBL4677872

SCHEMBL4677872

O=C(O)/C(O)=C/C(=O)c1ccc(S(=O)(=O)c2ccccc2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOX P28300 4/20 0.44
LOXL2 Q9Y4K0 3/20 0.44
MAOA P21397 1/20 0.44
HSD17B1 P14061 2/20 0.43
HSD17B2 P37059 2/20 0.43
HTR6 P50406 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
LMNA P02545 1/20 0.40
PPARG P37231 1/20 0.40
NCOA2 Q15596 1/20 0.40
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
ALDH1A1 P00352 4/20 0.39
POLB P06746 3/20 0.39
MEN1 O00255 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677875 1.00 LOX (0.44) LOXLOXL2MAOAHSD17B1HSD17B2
SCHEMBL4675148 0.87 CFTR (0.38) LOXLOXL2MAOAHSD17B1HSD17B2
SCHEMBL4674498 0.87 TDP1 (0.46) LOXMAOAHSD17B1HSD17B2NPSR1
SCHEMBL4674495 0.87 TDP1 (0.46) LOXMAOAHSD17B1HSD17B2NPSR1
SCHEMBL4675146 0.87 CFTR (0.38) LOXLOXL2MAOAHSD17B1HSD17B2
SCHEMBL4675381 0.81 HTR6 (0.40) HTR6NPSR1ALDH1A1POLBMEN1
SCHEMBL4675379 0.81 HTR6 (0.40) HTR6NPSR1ALDH1A1POLBMEN1
SCHEMBL8825020 0.79 LOX (0.53) LOXLOXL2MAOAHSD17B1HSD17B2
SCHEMBL4671823 0.74 CA2 (0.43) LOXLOXL2MAOAHTR6NPSR1
SCHEMBL4671828 0.74 CA2 (0.43) LOXLOXL2MAOAHTR6NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 LOX 3549/4885LOXL2 4446/4885MAOA 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.